FDA History and Major Milestones

The U.S. Food and Drug Administration traces a legislative and institutional arc spanning more than a century, shaped by public health crises, technological change, and expanding statutory authority. This page covers the foundational laws, landmark milestones, organizational evolution, and regulatory decision points that define the FDA's scope and function. Understanding this history is essential to interpreting how the agency's current authorities, centers, and approval frameworks came to exist.

Definition and Scope

The FDA is a federal agency within the Department of Health and Human Services (HHS), charged with regulating the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, food, cosmetics, dietary supplements, tobacco products, and radiation-emitting devices. Its statutory authority derives primarily from the Federal Food, Drug, and Cosmetic Act (FD&C Act), first enacted in 1938 and amended dozens of times since, codified at 21 U.S.C. §§ 301–399i.

The agency's regulatory reach extends to approximately 20 cents of every dollar spent by U.S. consumers, according to the FDA's own estimates of regulated product categories. That scope includes more than $2.8 trillion in annual consumption of FDA-regulated products, encompassing domestic manufacturing and import pathways across more than 300 product categories.

The FDA's mission and authority — detailed further on the FDA Mission and Authority page — are bounded by statute, meaning the agency can act only where Congress has granted explicit power. This constraint makes the legislative history of the FDA inseparable from its operational scope at any given moment.

How It Works

The FDA's history is best understood as a series of legislative expansions triggered by documented failures that existing law could not address. Each major statute added jurisdiction, enforcement tools, or procedural requirements.

Key legislative milestones in chronological order:

  1. 1906 — Pure Food and Drugs Act: The first federal law prohibiting adulterated or misbranded food and drugs in interstate commerce, administered by the Bureau of Chemistry within the Department of Agriculture. It did not require pre-market approval or proof of safety.

  2. 1938 — Federal Food, Drug, and Cosmetic Act (FD&C Act): Passed after a sulfanilamide elixir formulated with diethylene glycol killed approximately 107 people in 1937 (FDA historical account). This law for the first time required manufacturers to demonstrate safety before marketing a new drug. The Bureau of Chemistry was reorganized into the Food and Drug Administration, formally established under that name in 1930.

  3. 1962 — Kefauver-Harris Drug Amendments: Enacted after thalidomide — approved abroad but blocked in the U.S. by FDA reviewer Frances Kelsey — caused thousands of birth defects internationally. These amendments required manufacturers to demonstrate both safety and efficacy before approval, a requirement codified at 21 U.S.C. § 355(d). They also established the modern framework for FDA clinical trials oversight.

  4. 1976 — Medical Device Amendments: Created the three-class system for medical device regulation and established the 510(k) clearance process and Premarket Approval (PMA) pathway after failures involving intrauterine devices and other products caused documented patient harm.

  5. 1983 — Orphan Drug Act: Provided market exclusivity and financial incentives for drugs targeting diseases affecting fewer than 200,000 U.S. patients. By 2022, more than 900 orphan designations had resulted in approved products, according to the FDA Office of Orphan Products Development. The FDA Orphan Drug Designation framework traces directly to this statute.

  6. 1992 — Prescription Drug User Fee Act (PDUFA): Authorized the FDA to collect fees from pharmaceutical manufacturers to fund drug review operations, substantially reducing median new drug application review times. PDUFA has been reauthorized six times, most recently as PDUFA VII in 2022 (FDA PDUFA page).

  7. 1997 — FDA Modernization Act (FDAMA): Expanded accelerated approval pathways, introduced fast-track designation, and reformed device regulation. This is the statutory basis for pathways described on the FDA Accelerated Approval Pathways page.

  8. 2009 — Family Smoking Prevention and Tobacco Control Act: Granted FDA authority to regulate tobacco products for the first time, establishing the Center for Tobacco Products (CTP). The scope of FDA tobacco regulation derives entirely from this statute.

  9. 2011 — FDA Food Safety Modernization Act (FSMA): The most significant overhaul of food safety law since 1938, shifting the agency's approach from reactive to preventive. FSMA's full scope is covered on the FDA Food Safety Modernization Act page.

  10. 2016 — 21st Century Cures Act: Accelerated approval of new medical devices and drugs, expanded the use of real-world evidence, and introduced reforms to FDA digital health and software regulation.

Common Scenarios

Legislation triggered by product failures: The 1937 sulfanilamide disaster, thalidomide in the early 1960s, and Dalkon Shield litigation in the 1970s each produced statutes. This pattern — crisis, documentation, legislation — repeats throughout the FDA's history and explains why authority is siloed by product category rather than organized around a unified risk framework.

Contrast: Pre-1938 vs. Post-1938 burden of proof. Before the FD&C Act, manufacturers bore no pre-market obligation. Post-1938, the burden shifted: a manufacturer must affirmatively demonstrate that a new drug is safe before interstate distribution. Post-1962, that burden expanded to include efficacy. This two-stage shift is the most structurally significant change in the FDA's history and governs every new drug application submitted today.

Emergency authority expansions: The FDA Emergency Use Authorization mechanism — codified at 21 U.S.C. § 564 — was added by the Project BioShield Act of 2004, after the anthrax attacks of 2001 revealed gaps in the agency's authority to deploy unapproved medical countermeasures rapidly. This pathway was subsequently used for H1N1 influenza products in 2009, Ebola diagnostics in 2014, and COVID-19 vaccines and therapeutics beginning in 2020.

International comparison — thalidomide divergence: The FDA's refusal to approve thalidomide in the U.S., while regulatory bodies in West Germany and the United Kingdom did approve it, is the most-cited evidence that the FDA's pre-approval efficacy requirement provides a meaningful safety buffer distinct from approval processes in peer countries.

Decision Boundaries

The FDA's authority is bounded by three structural limits that define when and how it can act:

1. Statutory jurisdiction. The FDA can only regulate product categories Congress has assigned to it. Dietary supplements, for example, are regulated under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which does not require pre-market safety or efficacy review — a deliberate legislative choice that creates a structurally different burden than applies to drugs. This contrast is central to FDA dietary supplement regulation.

2. Interstate commerce nexus. The FD&C Act generally applies to products in or affecting interstate commerce. Products manufactured and sold entirely within a single state may fall outside FDA jurisdiction, though this boundary has narrowed over decades of court interpretation.

3. Product classification triggers pathway. A product's regulatory pathway depends on how it is classified — drug, device, biologic, food, or combination product. Classification determines whether a manufacturer files a New Drug Application, a Biologics License Application, or pursues device clearance. Disputes over classification are resolved by the FDA's Office of Combination Products, established by the Medical Device User Fee and Modernization Act of 2002.

For a structured overview of how these authorities fit together across the agency's organizational units, the FDA overview and the FDA Organizational Structure page provide the institutional context within which this legislative history operates.

Read Next

FDA Budget, Funding Sources, and User Fees The FDA operates through a hybrid funding model that draws on both congressional appropriations and industry-paid user fees — a... FDA Centers and Offices: A Complete Breakdown The U.S. Food and Drug Administration is organized into a network of product-specific centers and cross-cutting offices, each... FDA Organizational Structure and Leadership The U.S. Food and Drug Administration operates through a defined hierarchy of offices, centers, and leadership positions that...